Technical Analysis for INSM - Insmed, Inc.

Grade Last Price % Change Price Change
D 33.07 -1.64% -0.55
INSM closed down 1.64 percent on Friday, April 16, 2021, on 56 percent of normal volume.
Earnings due: Apr 28
*** please verify all earnings dates ***

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Down Down Flat
Historical INSM trend table...

Date Alert Name Type % Chg
20 DMA Resistance Bearish 0.00%
Bearish Engulfing Bearish 0.00%
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 0.00%
Outside Day Range Expansion 0.00%
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup -1.64%
MACD Bullish Signal Line Cross Bullish -1.64%
Up 3 Days in a Row Strength -1.64%
Gapped Up Strength 0.15%
Oversold Stochastic Weakness 0.15%
New Downtrend Bearish 4.39%
Older End-of-Day Signals for INSM ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
Outside Day about 9 hours ago
Down 3% about 9 hours ago
Non-ADX 1,2,3,4 Bearish Retracement Entry about 9 hours ago
Fell Below Previous Day's Low about 9 hours ago
60 Minute Opening Range Breakdown about 9 hours ago
View Earlier Intraday Alerts

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Insmed, Inc. Description

Insmed Incorporated, a biopharmaceutical company, focuses on developing and commercializing targeted inhalation therapies for patients battling serious lung diseases. Its lead candidate ARIKACE is engineered to deliver a proven and potent anti-infective directly to the site of serious lung infections to improve the treatment for two identified patient populations comprising cystic fibrosis (CF) patients with Pseudomonas aeuruginosa lung infections and patients with nontuberculous mycobacteria lung infections (NTM). The company's Phase III registrational study of ARIKACE in CF patients in Europe and Canada has completed enrollment; and Phase II clinical trial in NTM patients is under way with clinical results. Insmed Incorporated was founded in 1999 and is headquartered in Monmouth Junction, New Jersey.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Infectious Diseases Cystic Fibrosis Microbiology Infectious Causes Of Cancer Bacterial Diseases Pseudomonas Tuberculosis Bacteriology Lung Diseases Lung Infection Lung Infections Mycobacterium Nontuberculous Mycobacteria

Is INSM a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 45.405
52 Week Low 19.25
Average Volume 923,942
200-Day Moving Average 34.36
50-Day Moving Average 37.30
20-Day Moving Average 33.84
10-Day Moving Average 32.91
Average True Range 1.73
ADX 23.63
+DI 19.85
-DI 28.71
Chandelier Exit (Long, 3 ATRs ) 33.23
Chandelier Exit (Short, 3 ATRs ) 35.73
Upper Bollinger Band 37.36
Lower Bollinger Band 30.32
Percent B (%b) 0.39
BandWidth 20.80
MACD Line -1.27
MACD Signal Line -1.38
MACD Histogram 0.1098
Fundamentals Value
Market Cap 3.37 Billion
Num Shares 102 Million
EPS -4.09
Price-to-Earnings (P/E) Ratio -8.09
Price-to-Sales 22.11
Price-to-Book 11.27
PEG Ratio 0.00
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 35.32
Resistance 3 (R3) 35.34 34.62 34.95
Resistance 2 (R2) 34.62 34.04 34.61 34.82
Resistance 1 (R1) 33.84 33.69 33.48 33.82 34.69
Pivot Point 33.12 33.12 32.94 33.11 33.12
Support 1 (S1) 32.34 32.54 31.98 32.32 31.45
Support 2 (S2) 31.62 32.19 31.61 31.32
Support 3 (S3) 30.84 31.62 31.20
Support 4 (S4) 30.82